The use of human ultralente is limited by great intraindividual variability in overnight plasma insulin profiles

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 60, Issue 5, 2000, Pages 341-348

  Lindstrom, T ^a   Olsson, P O ^a   Arnqvist, H J ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Basal insulin; Pharmacokinetics; Type 1 diabetes; Ultralente

Indexed keywords

HUMAN INSULIN; INSULIN ZINC SUSPENSION;

ADULT; ARTICLE; CLINICAL ARTICLE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MALE; PRIORITY JOURNAL;

EID: 0033821460     PISSN: 00365513     EISSN: None     Source Type: Journal    
DOI: 10.1080/003655100750019242     Document Type: Article

References (20)

1. The dawn phenomenon, an early morning glucose rise: Implications for diabetic intraday blood glucose variation
2. Overnight metabolic control with bedtime injection of intermediate-acting insulin or continuous subcutaneous insulin infusion
3. Early morning glycaemia and the metabolic consequences of delaying breakfast/morning insulin. A comparison of continuous subcutaneous insulin infusion and multiple injection therapy with human isophane or human ultralente insulin at bedtime in insulin-dependent diabetics
4. Continuous subcutaneous insulin infusion (CSII), multiple injections (MI) and conventional insulin therapy (CT) in self-selecting insulin-dependent diabetic patients. A comparison of metabolic control, acute complications and patient preferences
5. Effectiveness of human ultralente versus NPH insulin in providing basal insulin replacement for an insulin lispro multiple daily injection regimen. A double-blind randomized prospective trial. The Canadian Lispro Study Group
6. Absorption of injected insulin: A clinical-pharmacological study
7. The subcutaneous absorption of human or bovine ultralente insulin formulations
8. Human, porcine and bovine ultralente insulin: Subcutaneous administration in normal man
9. Pharmacokinetics of long-acting (ultralente) insulin preparations
10. Human ultralente insulin
11. Free and total insulin as determined after precipitation with polyethlene glycol: Analytical characteristics and effects of sample handling and storage
12. Hypoglycaemia caused by atypical insulin antibodies in a patient with benign monoclonal gammopathy
13. A comparison of morning and bed-time ultralente administration when using multiple injections in adolescence
14. Use of human ultralente as the basal insulin component in treatment of patients with IDDM
15. A comparison of human ultralente- and lente-based twice-daily injection regimens
16. Prevention of early-morning hyperglycemia in IDDM patients with long-acting zinc insulin
17. Insulin pharmacokinetics
18. Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs
19. Long-acting insulin analogs